- Home
- UBFO vs SGMT Comparison
UBFO vs SGMT Comparison
Compare UBFO & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UBFO
- SGMT
- Stock Information
- Founded
- UBFO 1987
- SGMT 2006
- Country
- UBFO United States
- SGMT United States
- Employees
- UBFO N/A
- SGMT N/A
- Industry
- UBFO Major Banks
- SGMT
- Sector
- UBFO Finance
- SGMT
- Exchange
- UBFO Nasdaq
- SGMT Nasdaq
- Market Cap
- UBFO 175.9M
- SGMT 165.4M
- IPO Year
- UBFO N/A
- SGMT 2023
- Fundamental
- Price
- UBFO $9.86
- SGMT $4.12
- Analyst Decision
- UBFO
- SGMT Strong Buy
- Analyst Count
- UBFO 0
- SGMT 7
- Target Price
- UBFO N/A
- SGMT $25.71
- AVG Volume (30 Days)
- UBFO 28.4K
- SGMT 877.5K
- Earning Date
- UBFO 04-17-2025
- SGMT 03-24-2025
- Dividend Yield
- UBFO 4.87%
- SGMT N/A
- EPS Growth
- UBFO N/A
- SGMT N/A
- EPS
- UBFO 0.86
- SGMT N/A
- Revenue
- UBFO $48,600,000.00
- SGMT N/A
- Revenue This Year
- UBFO N/A
- SGMT N/A
- Revenue Next Year
- UBFO N/A
- SGMT N/A
- P/E Ratio
- UBFO $11.47
- SGMT N/A
- Revenue Growth
- UBFO N/A
- SGMT N/A
- 52 Week Low
- UBFO $7.02
- SGMT $2.39
- 52 Week High
- UBFO $10.49
- SGMT $7.64
- Technical
- Relative Strength Index (RSI)
- UBFO 49.27
- SGMT 43.11
- Support Level
- UBFO $9.87
- SGMT $3.96
- Resistance Level
- UBFO $10.17
- SGMT $4.83
- Average True Range (ATR)
- UBFO 0.17
- SGMT 0.38
- MACD
- UBFO 0.03
- SGMT -0.04
- Stochastic Oscillator
- UBFO 64.77
- SGMT 13.39
About UBFO United Security Bancshares
United Security Bancshares operates as the holding for United Security Bank. It provides commercial banking services to the business and professional community, and individuals located in Fresno, Madera, Santa Clara, and Kern Counties. It offers checking and savings accounts, deposits, mortgage loans, credit and debit cards, safe deposit boxes, automated teller machines, wire transfers, money market accounts, mobile banking, and wealth management services. The company's primary sources of revenue are interest income from loans and investment securities.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).